Crossmark

Multiplex LC–MS/MS assay for simultaneous quantification of artesunate and its active metabolite dihydroartemisinin with pyronaridine, proguanil, cycloguanil, and clindamycin in pharmacokinetic studies

Crossref DOI link: https://doi.org/10.1186/s12936-025-05387-6

Published Online: 2025-05-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pfaffendorf, Christoph

Mischlinger, Johannes

Dejon-Agobé, Jean Claude

Maïga-Ascofaré, Oumou

Ahenkan, Ebenezer

Adegnika, Ayôla Akim

Ramharter, Michael

Wicha, Sebastian G.
Funding

Funding for this research was provided by:

Deutsches Zentrum für Infektionsforschung (TTU 03.709)

EDCTP2 (ASAAP RIA2017MC-2022)

Universität Hamburg
License Information

Text and Data Mining valid from 2025-05-27

Version of Record valid from 2025-05-27
More Information

Article History

Received: 5 December 2024

Accepted: 26 April 2025

First Online: 27 May 2025

Declarations

:

: The study conformed to the Declaration of Helsinki and Standard Operating Procedures that meet current regulatory requirements and guidelines laid down by the International Conference on Harmonisation for Good Clinical Practice in Clinical Studies. The clinical trial was approved by the relevant Independent Ethics Committees, national Institutional Review Boards, and local regulatory authorities at Centre de Recherches Médicales de Lambaréné (CERMEL) (Lambaréné, Gabon). The study protocol was registered online before start of recruitment into this clinical trial (pactr.samrc.ac.za, PACTR202008909968293).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below